An Evolution in Prospective Healthcare: Digital Biomarkers

 The human species is an intelligent machine that can detect when one's health is excellent or terrible. Healthcare practitioners evaluate specific biological factors for optimal functioning to determine the body's state of health. These biological factors are called biomarkers because they serve as indicators of how well or poorly various bodily organs are operating.

In the past, general health issues have been evaluated using clinical tests that measure things like blood pressure, cholesterol, body temperature, or pulmonary function. While a number of genetic and molecular abnormalities are crucial biomarkers for a more complex disease like cancer.

With the advent of powerful digital technologies, the healthcare sector is shifting toward new techniques of health evaluation, even though these biomarkers continue to play a significant role in the precise detection and early prognosis of the diseases. Large, diversified, and complicated data collecting relating to human health now offers a wealth of opportunities because to the rising popularity of wearable technology, such as smartwatches with built-in heart rate monitors and step counters.

Digital biomarkers are the measurable physiological and behavioural data that are measured and gathered by portable, wearable, implantable, or consumable digital devices. These devices' data are often used to forecast linked health outcomes and show how lifestyle choices affect health.

Sources of Information that serve as Digital Biomarkers

Smart devices, the Internet of Things (IoT), and big data technologies are helping individuals live healthier lives and keep track of their daily activities. Additionally, the information gathered by these devices aids researchers in efficiently analysing a large volume of complicated data and forecasting impending risks to human health.

Due to such immense benefits and easy access to public health information, the global digital biomarkers market is growing significantly. According to the BIS Research report, the market was valued at $1.808 billion in 2021 and is expected to reach $16.174 billion by 2028. It is expected to grow at a CAGR of 36.06% during the forecast period 2022-2028.

Relevance of Biomarkers in Healthcare

The use of biomarkers is an important tool for gathering important data at several phases, including disease detection and prevention, identifying potential disease risks, and tracking the effects of treatment on the body. Additional advantages of using biomarkers in medicine include the following:

• Enhancing knowledge of the pathogenic mechanisms underlying chronic illnesses
• Early illness detection in the at-risk asymptomatic population and provision of preventative treatment
• Establishing a precise description of the disease while also making an accurate and conclusive diagnosis
• An important part in the growth of precision medicine.
• Choosing the appropriate course of action based on the disease's severity
• Keeping an eye on how the patients are responding to the treatment.
• Identification of people with a high likelihood of suffering negative side effects from a treatment based on their vital signs
• Early identification of illness recurrence or developing complications

Biomarkers' Technological Evolution

Digital biomarkers are now commonly employed for therapy follow-up and diagnosis. They are objective and quantitative instruments for evaluating biological processes that are connected to symptoms, hazards, and common differences in big populations as well as medical indications.

Wearable technology, smartphone apps, and data integration software rule the global market for digital biomarkers. Numerous digital biomarker applications, including fitness tracking, step counting, vital sign monitoring, sleep pattern analysis, and food management, are available. Additionally, it can be used to diagnose and treat gastrointestinal problems, cardiovascular ailments, neurological problems, behavioural and mood disorders, sleep and movement issues, and fertility tracking, among other conditions.

Conclusion

The integration of technology has resulted in a tremendous increase in knowledge about numerous areas of human health. It contributes to the creation of improved cures and treatment methods, as well as the accessibility of healthcare services. Similarly, the rise of the field of digital biomarkers has piqued the interest of the healthcare business, which is looking for advancements that will likely revolutionise the knowledge and practise of healthcare.

Liquid Biopsy Creating New Opportunities for Cancer Diagnostics

 Liquid biopsy is gaining popularity in healthcare and medical research because it provides an efficient and non-invasive means of detecting and diagnosing cancer. This field is always revealing new opportunities in the healthcare system. Liquid biopsy is a non-invasive medical procedure which holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. The report includes market estimation for tests/services, instruments, kits and consumables used for liquid biopsies of different oncology and non-oncology disorders. 

A liquid biopsy enables physicians to assess tumor-related data using a simple blood test. As researchers generate data that has the potential to lead to unparalleled biological insight, the complexity of data analysis is increasing. One of the significant prospects in the global liquid biopsy market is increased investment in R&D of liquid biopsy goods and services, as well as various research funding's.

Acknowledging the rapidly growing popularity of liquid biopsy in the healthcare market, BIS Healthcare has compiled a report titled Liquid Biopsy Market - A Global and Regional Analysis According to the market research report, The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine. The countries such as China, Japan, India, Australia, and South Africa possess population with high risk of developing mutations in high numbers and offer a great opportunity for the expansion of the liquid biopsy market.

The factors propelling the growth of the liquid biopsy market are the rising prevalence of cancers coupled with the increasing NCI budget allocation and the growing adoption of inorganic growth strategies among key players in the market. Moreover, factors hindering the market growth are uncertain reimbursement and regulatory policies, false negatives and positives, and existing diagnostic confidence in standard tumor biopsies.

Recent Developments in the Global Liquid Biopsy Market

•    Product Launch in 2020: Sysmex Corporation launched liquid biopsy RUO kits in EMEA region. The kits name is Plasma-SeqSensei, and it is used for non-small cell lung cancer (NSCLC), melanoma, and thyroid cancer.

•    Partnership: In 2021, Illumina, Inc. collaborated with Bristol Myers Squibb to innovate and enhance companion diagnostics for therapy selection to further precision oncology. TSO 500 ctDNA is one of the first liquid biopsy assays to enable comprehensive genomic profiling for therapy selection.

•    Collaboration: In 2021, QIAGEN collaborated with Sysmex Corporation for the development and commercialization of cancer companion diagnostics using NGS and Plasma-Safe-SeqS technology.

During COVID-19, the government enacted a number of restrictions, including travel bans, quarantines, curfews, business closures, and closures. As a result, the price of services associated to COVID-19 rose. The COVID-19 epidemic has caused a number of problems, including production problems, shipping problems, incorrect demand predictions, and operational difficulties.

Additionally, because COVID-19 decreased the effectiveness of employees' work potential, it had an effect on their health and safety. However, as a result of the pandemic's increased demand for testing services, the COVID-19 market expanded. Overall, COVID-19 has had a low-moderate impact on market size. A modest reduction in sales has been noticed by some market participants.

The financial situation is already improving, though. The earliest COVID-19 pandemic phases, which included complete lockdowns across nations and large cities, disrupted the supply chain and led to the drop in earnings. For the majority of the world's major markets, the effect period ran from the end of the first quarter to the second quarter of 2020. However, the pandemic has significantly improved the potential prospects for liquid biopsy and is anticipated to indirectly help improve the outlook for market growth.

North America is the leading contributor in the global liquid biopsy market. It contributed approximately 54.17% to the North American market value in 2021. This region is anticipated to grow at a CAGR of 19.22% during the forecast period 2022-2032 and will continue dominating the market in 2032.

The prominent players in this market are Bio-Rad Laboratories, Inc., F-Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Laboratory Corporation of America Holdings, Natera, Inc., Guardant Health, Biocept, Inc., Eurofins Scientific, NeoGenomics Laboratories, Sysmex Corporation, and PerkinElmer Inc., Elypta, Micronoma, Dxcover Limited, LungLife AI, Inc., Epic Sciences, Abcodia Ltd., and Bioscience Institute S.p.A.

RELATED MARKET REPORTS

Global Flow Cytometry in Oncology Market – Analysis and Forecast, 2021-2026 

Global Solid Tumor Testing Market – Analysis and Forecast, 2019-2030

 Global Somatic Genetic Testing Market – Analysis and Forecast, 2020-2030 

Global Rare Disease Diagnostics Market – Analysis and Forecast, 2020-2030 

Global Oncology Precision Medicine Market – Analysis and Forecast, 2020-2030 

Global Hematologic Malignancies Testing Market – Analysis and Forecast, 2018-2025

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Rise in Application of Robotics in Medical Field Propelling the Healthcare Industry

 

The healthcare industry as a whole is undergoing significant transformations in order to improve or maintain high-quality care while reducing costs. Factors like the ageing population and disparities in care standards between developed and developing economies make resolving these issues difficult. As it is the most effective treatment option, minimally invasive surgery has a lot of potential in the healthcare industry. Robotics has gained a lot of traction in the healthcare industry over the last few years. 

 The market for robotic-assisted imaging technologies is expected to expand rapidly over the forecast period, owing to rising chronic disease incidence, an ageing global population, improved reimbursement policies, and government initiatives and funding to develop technologically advanced products. The market’s growth slowed slightly in 2020 due to the COVID-19 pandemic; however, the market began to recover in 2021 and is expected to rise steadily through the end of 2030. 

 

The global robotic-assisted imaging technologies market is influenced by a number of factors. The rise in minimally invasive surgical procedures around the world, evolution in image modalities and features, and increased use of robotics in the medical field are all factors that are positively impacting the market’s growth. Some factors, on the other hand, will have a growth-limiting effect on the market. The major barriers to market growth are robotic failures leading to a low rate of adoption, lack of acceptance of robotic procedures, and an increase in the use of robotics in the medical field. 

According to BIS Research, Global Robotic-Assisted Imaging Technologies Market was valued at $617.7 million in 2020 and is projected to reach $2,207.8 million by the end of 2030, growing at a CAGR of 13.74% during the forecast period 2021-2030. 

The healthcare industry is evolving, with a focus on more informative advanced tools rather than traditional approaches. Robotic-assisted imaging technologies, for example, have been created to provide more precise and optimal diagnostic results. Despite the availability of a variety of strategies, the market’s hold on technology is fragmented and incomplete. 

By introducing technologically advanced products, robotic-assisted imaging technologies have revolutionised diagnostics practices. Robotic-assisted imaging systems are quickly becoming the most lucrative opportunities for major corporations, with many companies focusing solely on developing multiple diagnostic and treatment-focused products. The prominent players in this market are Becton, Dickinson and Company, Boston Scientific Corporation, Terumo Corporation, Varian Medical Systems, Inc., Eckert & Ziegler BEBIG AG, HealthTronics, Inc., Teleflex Incorporated, and Johnson & Johnson among others.

BIS RESEARCH’S TAKE ON THE INDUSTRY

What is the addressable market size and forecast based on region?

North America dominates the global robotic-assisted imaging technologies market. The highest market share of the North America robotic-assisted imaging technologies market can be attributed to the high prevalence of chronic diseases such as cardiovascular diseases and cancer, among others, the growing geriatric population, and the high reimbursement rates. The North America medical device market is the early adopter of the latest technologies and has now turned into a technological hub for companies offering advanced solutions to the healthcare market.

The Europe robotic-assisted imaging technologies market is one of the markets with high growth potential. The major driving factors for cancer in Europe include the availability of good medical facilities, preference of interventional procedures by European people, high consumption of alcohol, and high preference and incidence of cancer.

The Asia-Pacific robotic-assisted imaging technologies market is one of the lucrative markets with immense potential for expansion by key players of the global robotic-assisted imaging technologies market.

The Asia-Pacific robotic-assisted imaging technologies market is expected to grow at the fastest rate during the forecast period. This can be attributed to the massive geriatric population base, demand for minimally invasive and non-invasive surgical procedures, and high prevalence rates of cancer.

What are the key trends of the global robotic-assisted imaging modalities market?

Robotic-assisted imaging technologies are one of the disruptive classes of medical devices and are influenced by various technological trends. 

• Shift Toward Minimally Invasive Procedures
• The shift to minimally invasive procedures is one of the breakthroughs in healthcare.

What are the market shares of key competitors in the global robotic-assisted imaging modalities market? 

The significant potential of robotic-assisted imaging technologies in addressing several types of cancers that are outcomes of sedentary lifestyles as well as geriatric diseases have made the global robotic-assisted imaging technologies market one of the most lucrative industries for players in the global healthcare scenario.

Becton, Dickinson and Company, Boston Scientific Corporation, and Terumo Corporation are the major contributors to the global robotic-assisted imaging technologies market. Extensive 13 product portfolio comprising supporting devices and treatment devices are the key factors for the dominance of these companies in the global market.

 RELATED MARKET REPORTS 

Global AI-Enabled X-Ray Imaging Solutions Market 

Global AI-Enabled Medical Imaging Solutions Market 

Global AI-Enabled Imaging Modalities Market 

Global Robotic Assisted Surgery Market

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Growing Incidence of Cancer Drives the Companion Diagnostics (CDx) Market

 

Precision medicine has become increasingly well-liked and recognized over the past ten years as a result of its ability to help physicians switch from a generalised, target-based approach to therapy that relies less on trial and error. The development of sophisticated methods of diagnosis and treatment, including liquid biopsy, companion diagnostics, and next-generation sequencing, was made possible by technical advances in the elements that make up the basic science of precision medicine. Out of the three, companion diagnostics refers to the process of developing the targeted medicine along with the biomarker-based testing. Companion diagnostics also aid in locating patient-related data and make it easier to utilise focused therapies.

Market Overview

The companion diagnostics market analysis by BIS Research projects the market to grow at a significant CAGR of 12.45% during the forecast period, 2020-2030. The global companion diagnostics market generated $1,764.7 million revenue in 2019, in terms of value. 

The rising prevalence of cancer, the increasing desire for precision medicine, and the co-development of drugs and diagnostics have been identified as the primary market drivers for companion diagnostics. However, there are considerable obstacles that are limiting market expansion. The reimbursement situation is unpredictable, and the synchronization between treatments and diagnostics in marketing and distribution channels is not strong.

Several opportunities in the healthcare sector, like multiple biomarker-based development, new developments in NGS techniques, commercialization, etc., support the growth of the CDx market. Leukemia, breast, lung, ovarian, colon, and stomach cancers are only a few of the malignancies for which CDx has been successfully commercialized. All of this has resulted in new businesses entering the market and initiatives conducted by various organizations to create effective apps for difficulties including typical infections, cardiovascular health issues, metabolic disorders, and neurodegenerative health issues.

Expert Quote

According to the report published by BIS Research “North America is the leading contributor in the global companion diagnostics market and contributed approximately 56.69% to the global market value in 2019. This region is anticipated to grow at a significant CAGR during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Asia-Pacific region is expected to grow at the highest CAGR of 20.99% during the forecast period. In addition, the region of Europe also contributed a significant share of 25.95% to the global market in 2019.”

Scope of the Market Intelligence on the Global Companion Diagnostics Market

The scope of the report primarily evaluates FDA-approved companion diagnostics products that are commercialized in the U.S. as well as other regions. In addition, the study also includes companion diagnostics products that have received approvals for commercialization from the European Medicines Agency (EMA), Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA), and National Medical Products Administration (NMPA; formerly known as China Food and Drug Administration or the CFDA). 

Key Companies in the Global Companion Diagnostics Market

The key manufacturers who have been contributing significantly to the global companion diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, bioMérieux S.A., Danaher Corporation , DiaCarta, Inc., F. Hoffmann-La Roche Ltd, ICON plc, Illumina, Inc., Invivoscribe Technologies, Inc. , Myriad Genetics, Inc. , Novogene Corporation, QIAGEN N.V. , Thermo Fisher Scientific Inc among others.

RELATED MARKET REPORTS 

Pharmacogenomics Services Market - A Global and Regional Analysis

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Role of Constrained Peptides in Drug Discovery

The exponential rise in the renaissance of peptide therapeutics in the pharmaceutical industry is largely attributed to the recent success of peptides as therapeutic agents and advancements in synthetic chemistry. Constrained peptide therapeutics demonstrates a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, innovative route of administration, and synthesis in peptide therapeutics leading to the advancements in the development of constrained peptides.

The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to grow to $10,367.2 million by 2031, growing at a projected CAGR of 90.37% during the forecast period 2020-2031. The market is favored by the development and launch of pipeline constrained peptide drugs and the ability to target varied biological interventions with innovate route of administration. The gradual increase in the prevalence of oncology and rare diseases globally has fueled the constrained peptide drugs market. 

 Several key players such as Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc., and Bicycle Therapeutics PLC are focusing on expanding their product portfolios, subsequently strengthening their positions in the market. They have been expanding their product portfolios for diversified biological interventions, including neurology, metabolic, and anti-infectives

Addressable Market Size and Forecast based on Region

In 2023, the global constrained peptide drugs market is anticipated to be $60.1 million, which is expected to reach $10367.2 million in 2031, growing at the CAGR of 90.37 % during the forecast period 2020-2031. The North America global constrained peptide drugs market is expected to be valued High in 2023 and the region is expected to be the leading contributor in the market. The growing prevalence of genetic disorders, and chronic diseases such as lung cancer and tumors, and the early launch of pipeline products are factors that lead to the dominance of North America in the global constrained peptide drugs market. Furthermore, North America is home to several constrained peptide-based manufacturers as well as service providers, and the availability of funding for the new entrants by venture capitalists is driving the growth of the market in the region. 

 Followed by North America, Europe held the second-largest share in the global market. The increase in the market growth can be attributed to factors such as research grants and funding by government and non-profit organizations, the launch of research and development programs by the biopharmaceutical companies and research organizations, which has driven the growth of the region.

Current Scenario of the Constrained Peptide Drugs Pipeline

As per the clinical trial registry, there are 18 clinical studies ongoing at different stages evaluating the potential of constrained peptides as therapeutic agents for a diversified range of indications. The most advanced constrained peptide pipeline drug candidates include Zilucoplan (RA101495), Rusfertide (PTG-300), PNR-943, BT1718, and BT5528. Zilucoplan (RA101495), developed by Union Chimique Belge S.A. is under phase III clinical trial for treating subjects with Generalized Myasthenia Gravis.It is followed by Rusfertide (PTG-300) and PNR-943 developed by Protagonist Therapeutics, Inc. in phase II for indications polycythemia vera, hereditary hemochromatosis, and ulcerative colitis.

 Other companies conducting clinical studies of constrained peptide candidates include Bicycle Therapeutics PLC, Aileron Therapeutics, Inc., Polyphor Limited, and Santhera Pharmaceuticals Holdings.

Most of the ongoing clinical studies are under the phase II stage and are being conducted in the U.S. The novel constrained peptide drugs are undergoing clinical evaluation as single agents for advanced solid tumors, lung cancer, blood disorders, inflammatory bowel diseases, rare diseases, and metabolic diseases. The most common route of administration followed in the ongoing clinical trial is intravenous followed by subcutaneous. Only two companies, Protagonist Therapeutics, Inc., and Santhera Pharmaceuticals, are targeting oral administration for their constrained peptide drugs treating patients with inflammatory bowel diseases and cystic fibrosis, respectively.

RELATED MARKET REPORTS 

Global Neoantigen Cancer Vaccine Market, 2023-2030

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Molecular Diagnostics Market Transforming the Healthcare Sector

 

A paradigm shift toward more accurate forms of diagnostics has been observed in the healthcare sector as a result of developments in the era of precision medicine. The precision medicine model refers to the personalization of medical care in light of each patient's unique characteristics. Precision medicine is a patient-centered approach to therapy that has made it possible to eliminate ambiguity in the drug trial-and-error process, thus cutting back on wasteful healthcare spending. With the incorporation of cutting-edge technologies and numerous applications, including companion diagnostics, liquid biopsy, and non-invasive prenatal testing, molecular diagnostics, a crucial component of the precision medicine model, has significantly contributed to the revolutionizing of the precision medicine sector.

The definition of molecular diagnostics is a diagnostic procedure that finds differences in genes, ribonucleic acids (RNAs), and proteins to determine whether a person is predisposed to a particular disease or has been identified as having that condition. It can also determine how likely it is that a certain treatment will be successful in treating the disease. The development of treatment that has changed the healthcare industry has been made possible by the market for molecular diagnostics.

According to the latest market intelligence report by BIS Research titled Molecular Diagnostics Market - A Global and Regional Analysis 2021-2031. The molecular diagnostics market is categorized into various segments such as product, application, technology, region, and end user. These segments are further divided into several sub-segments for a more in-depth analysis of the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World; and the molecular diagnostics market by product is segmented into kits and consumables, systems, software, and others.

The prevalence of chronic and infectious diseases, as well as cancers, is on the rise, and this market is expected to grow as a result. Other important factors driving this market growth include the high growth rate of the biomarker identification market, significant funding for research and development, and technological developments that have made molecular diagnostics more accurate. However, a number of issues, such as a dearth of testing facilities, an unclear reimbursement environment, and a holdup in the clearance of new molecular tests, are limiting the market's expansion.

The report, published by BIS Research, discusses about varied applications of the molecular diagnostics market. These include companion diagnostics, liquid biopsy, non-invasive prenatal testing, oncology, and genetic screening, among others. Besides hospitals, diagnostic centres, out-patient clinics, general practitioners, and research laboratories are also prominent end users of the molecular diagnostics market. Key manufacturers contributing significantly to the growth of diagnostics market are Abbott Laboratories, Bio-Rad Laboratories, Agilent Technologies, Inc., Dickinson and Company and Becton.

The emergence of molecular diagnostics as an integral part of the healthcare business is influencing technological breakthroughs as well as the creation of cost-effective diagnostic instruments and novel treatment techniques.

SERD Therapeutics- A Promising Treatment for Breast Cancer

 Globally, breast cancer in women has transcended lung cancer to account for the most cancer diagnoses and has created an urgent need for innovative advanced therapies. The burden of breast cancer incidence and mortality is growing alarmingly, which can be attributed to the rising population coupled with socioeconomic risk factors that impact breast cancer prevalence.

The global SERD (selective estrogen receptor degrader) therapeutics market was valued at $874.9 million in 2020 and is anticipated to reach $4,085.0 million by the end of 2030, growing at a projected CAGR of 16.7% during the forecast period 2020-2030. Endocrine therapy has long been considered as the mainstay for hormone receptor positive advanced or metastatic breast cancer. SERDs have shown significant potential to treat patients with endocrine-resistant breast cancer and naive patients with breast cancer.

The COVID-19 impact on the global SERD therapeutics market is low to moderate. Ongoing SERD therapy clinical trials were also not significantly impacted by COVID-19. For instance, Zentalis Pharmaceuticals, from its ongoing clinical trials, reported grade three events, including chest pain, back pain, hypertension, among others, which were attributed to COVID-19 and not ZN-c5. Rather, the company’s strong resilience reported further development and progress of under evaluation oral SERDs. Also, the companies are expecting more clinical trial readouts in 2021.

BIS RESEARCH’S TAKE ON THE INDUSTRY

What is the addressable market size and forecast based on region? 

North America currently dominates the global SERD therapeutics market. The factors contributing to the high demand for SERD therapy in North America are increasing incidences of breast cancer and the early launch of pipeline products in the U.S.

What are the most advanced pipeline products in the global SERD therapeutics market?

 Until 2018, Faslodex, developed by AstraZeneca Plc, was the only treatment available for estrogen receptor-positive, HER-2 negative, and advanced-stage breast cancer in postmenopausal women that have previously not undergone any hormonal therapy. Also, it is approved as monotherapy for the first-line treatment and as a combination therapy with Palbociclib. Multiple generics debuted in the following years in several countries, thereby impacting the sales of blockbuster Faslodex.

Most of the companies are targeting second-line treatments in postmenopausal women for breast cancer. The companies consider under-development SERDs as best-in-class oral assets with improved efficacy. Zenopharm LLC received small business innovation research (SBIR) phase I and II grant for ZB716 to perform and test tolerability, safety, and pharmacokinetics in humans.

What is the impact of novel drugs on available therapies? 

The recent launch of novel and emerging therapies for the treatment of breast cancer have demonstrated significant impact on the uptake of years old therapies in breast cancer. Kisqali and Verzenio have also been successful products in breast cancer treatment. Moreover, a number of novel therapies are under evaluation and express positive outcomes in breast cancer treatment. The limitations of available therapies and room for innovation of revolutionary therapies in breast cancer are likely to support the uptake of emerging therapies.

What is the potential of SERD therapy in breast cancer treatment? 

Nearly 80% of all breast cancers are hormone receptor-positive, of which approximately 70% are estrogen receptor alpha (Er-α). Inhibition of ER signaling is the focus of various breast cancer treatments, each with distinct mechanisms of action. Many patients eventually acquire resistance toward the available endocrine therapies leading to disease continuance and death. This remains a major challenge with the current standard care of breast cancer.

Since a majority of endocrine therapy resistance is attributed to ER-α based activity, shutting down the ER-α signaling could be a potential strategy to subdue this resistance. It can be achieved with the removal of ER-α from the cancerous cells by employing selective estrogen receptor degraders (SERDs). Preclinical and clinical results of SERDs have demonstrated a significant reduction in the number of resistance mechanisms in breast cancer patients. Although various SERDs are under evaluation, there is still space for the innovation and development of more efficacious SERDs with superior degradation characteristics.

RELATED MARKET REPORTS 

Global SERD Therapeutics Market - Focus on Product, Therapy, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030 

Global Female Technology (Femtech) Market - Analysis and Forecast, 2019-2030 

Global Next-Generation Breast Cancer Diagnostic and Screening Market - Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

 Global DNA Damage Response Drugs Market - Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Rising number of surgical procedures globally propels the demand for surgical instrument tracking devices

Surgical instrument tracking devices are systems that can combine scanning technology and application software. They help healthcare professionals to perform efficient and time-saving procedures. The surgical tracking devices are very useful in organizing surgical sets, cycle tracking, and documentation of instruments used, understanding the replacement of instruments, and other applications. 

 Surgical instruments have a shelf life, and manufacturers usually specify how many cycles they can be used for. A surgical instrument tracking system shows users how many cycles an instrument has completed and, in some cases, can prevent further use once the maximum number of cycles has been reached. This eliminates user discretion, and manual cycle counts, resulting in a safer process for patients. Additionally, the number of usage cycles completed by each instrument is critical information for staff when performing instrument maintenance or deciding whether or not to condemn or continue using these instruments. 

Moreover, an instrument tracking system that uniquely identifies every surgical instrument via unique codes or Automatic Identification and Data Capture (AIDC) technology ensures that staff gets to know the exact number of items being used on a patient. Additionally, RFID makes the counting automated and convenient, leading to better compliance on SOPs. This greatly reduces chances of “retained foreign bodies” by 0.3-1 cases per 1000 cases. 

The global surgical instrument tracking devices market was valued at $354.3 million in 2020 and is anticipated to reach $868.2 million by 2031, witnessing a CAGR of 9.16% during the forecast period 2021-2031. 

Surgical instrument tracking devices have revolutionized tracking and locating medical devices through the introduction of technologically advanced products and their increased adoption among their end users. Major manufacturers of these advanced technologies are located mainly in North America and Europe.

 

Market Size and Forecast based on Region

 North America region is the early adopters of advanced technologies for surgical instrument tracking devices. Many of the leading companies in the market are headquartered in this region and maintain a strong presence in the domestic market..

Market Shares of Key Competitors in the Global Market

 Steris plc dominates the global surgical instrument tracking devices market by holding high value of the market share in 2020. Followed by Steris plc, the market was dominated by Fortive Corporation and Case Medical, which held nearly high value more in 2020, respectively. 

 

Key Trends and Opportunities in the Market

 Key trends include a rise in demand for active RFIDs and the increasing use of web-based services. When compared to barcodes, RFIDs have become more popular. This is due to the advantages of RFIDs over barcode labeling, which includes the ability to perform multiple read-writes of data to the tag, higher data storage space, faster data transmission rate, and the ability to perform multiple dynamic data updates with rapid read speeds and batch reading capability. Many advances have been observed in the global surgical instrument tracking devices market since the FDA made it mandatory for hospitals and ambulatory centers to adopt monitoring systems for their surgical instruments. Manufacturers are pursuing the “More in Less” goal, aiming to include more services in a single product.

Key Development and Strategies 

Manufacturers in the market have recognized that barcodes and RFIDs are promising technologies with a bright future for the surgical instrument tracking devices industry. New offerings were present in the majority of the key developments mapped over the last five years (January 2016-March 2021). To remain ahead of the competition, companies have been concentrating more on product releases. Twelve product offerings and upgradation in the surgical instrument tracking devices market from January 2016 to March 2021 had a significant impact in increasing the market’s level of competitiveness. 

The market has witnessed a total of 32 key developments over the five years (January 2016-March 2021), with a majority of them being product offerings and upgradation accompanied by partnerships, alliances, and business expansions. Efforts are being made to bring more technologically innovative goods to market, each aimed at a particular unmet need. With the launch of new and updated devices with improved features, surgical instrument tracking devices technology has become increasingly possible to unlock new use cases.

Currently, most market players are involved in introducing new products and partnerships, alliances, and business expansions in the market. There is a potential in the market for mergers and acquisitions in the future as more and more start-ups are entering the market targeting specific applications, and key players are trying to consolidate their position in the market. Surgical instrument tracking devices have a promising outlook, and successful start-ups may enter into merger agreements with well-established players in the market. An increasing preference from a wide range of end users is expected to boost the demand for surgical instrument tracking devices in the market.

RELATED MARKET REPORTS 

Global Minimally Invasive Surgical Systems Market - Analysis and Forecast, 2021-2031

 Global Haptic Feedback Surgical Environment Market - Analysis and Forecast, 2021-2031

 Global Minimally Invasive Gastrointestinal Surgical Systems Market - Analysis and Forecast, 2021-2031 

Global 4K Medical Imaging Market - Analysis and Forecast, 2020-2030 

Global Minimally Invasive Surgical Systems Market – Analysis and Forecast, 2020-2030

Global Robotic Surgery Consumables Market – Analysis and Forecast, 2020-2030

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.

Emerging Devices Aiding in the Diagnosis and Treatment of Mental Health Issues

One of the most important aspects of someone's total welfare is their mental health. However, the inadequate diagnosis of the diseases is due to a lack of knowledge, associated societal stigma, and misunderstanding of mental health in government health-related  initiatives.

 With the widespread use of technology in recent years, mental health diagnosis has undergone significant development and faced the aforementioned challenges. For instance, the availability of mobile applications for mental health has improved self-monitoring among app users and patients. The apps provide cognitive behavior therapy (CBT) exercises, meditation therapy lessons, and capabilities for keeping track of your mood. Additionally, the COVID-19 pandemic raised awareness of issues with global mental health and sped up the use of teletherapy and other mobile mental health platforms.

The global emerging mental health devices and platforms market is projected to reach $18.7 billion by end of 2030, witnessing a compound annual growth rate (CAGR) of 24.7% during the forecast period 2021-2030. Moreover, the growth trend is anticipated to continue during the forecast period 2021-2030. The global emerging mental health devices and platforms market has been considerably impacted by 

 Addressable market size and forecast based on region

North America held the largest share in the global emerging mental health devices and platforms market in 2020, and the trend is anticipated to continue during the forecast period 2021-2030.

The advanced healthcare system, the presence of various mental health and telehealth companies, and a positive reimbursement landscape for mental health treatment will propel the growth of the region during the forecast period 2021-2030. Followed by North America, Europe held the second-largest share in the global market. The technological developments in the region and the presence of regional companies are expected to drive the growth of the region during the forecast period 2021-2030.

Asia-Pacific held the third-largest share in the global market in 2020. The technological advancements and entry of international players in the developed economies are expected to drive the growth of the region. Furthermore, the development of regional start-ups and a growing focus on mental health in emerging economies of the region are also expected to propel the growth of the market during the forecast period 2021-2030.

Key trends of the global emerging mental health devices and platform market

 The global emerging mental health devices and platforms market is influenced by various technology trends. The adoption of digital technologies had led to high user acceptability, a large customer base, and expansion in the services offered by the companies operating in the market. Digital technologies such as connected devices and mobile platforms for self-management were already predominant in the market, however, the rise of COVID-19 has further increased the adoption of the mental health platforms with remote monitoring capabilities. Furthermore, inclusion of digital mental health services in insurance and technology adoption for raw data analysis is anticipated to be ubiquitous owing to the surge in healthcare digitalization by the end of 2030.  

Market shares of key competitors in the global emerging mental health devices and platform market

The global emerging mental health devices and platforms market is significantly fragmented in nature owing to the existence of numerous regional companies and their limited geographical presence. The platform segment is highly fragmented in nature owing to the presence of various technologies such as digital therapeutics, teleconsultations, and mental health monitoring applications. The key companies operating in the segment include Calm, Headspace, Inc., AbleTo, Inc, Pear Therapeutics, Inc., and Talkspace. In the devices segment, however, only a limited number of companies operate owing to the regulations and pre-dominance of conventional mental health devices. The key companies operating in the segment include Neuronetics, Flow Neuroscience AB, Lief Therapeutics, Bioself Technology Ltd, and Ybrain, INC.

RELATED MARKET REPORTS 

Global Mobile Medical Apps Market: Focus on Category, Type, Application, Countries, Patents, Market , and Competitive Landscape - Analysis and Forecast, 2017-2025 

Global Emerging Mental Health Devices and Platforms Market Analysis and Forecast, 2021-2030

ABOUT BIS HEALTHCARE

 BIS healthcare vertical offers intelligence in the healthcare technology market for precision medicine, robotics and imaging, life sciences and biopharma, medical devices, digital health, and other emerging healthcare technologies, covering the entire industry spectrum. In the past eight years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating ‘Top 25 Voices’ in precision medicine on its InsightMonk platform for the past two years successfully.